TREATMENT OF STAGE I DIFFUSE AGGRESSIVE LYMPHOMAS

I期弥漫性甲状腺肿患者的剖腹手术期放射治疗 侵袭性淋巴瘤是中等成功的。 本研究旨在 提高放射治疗的疗效， 准备剖腹手术 在这项研究中，临床I期和IE患者 接受四个周期的ProMACE-MOPP化疗（ 最初使用的骨髓抑制药物剂量的大约75% 在ProMACE和MOPP中），随后进行累及野放疗至40戈伊。 那里 入组研究的62例可评价患者中，60例（97%） 完全缓解 有三次复发。 7例患者死亡： 两个从来没有达到一个完整的反应，和一个女人谁一直是 在四年多的时间里，她在第二次冠状动脉造影中死亡。 动脉搭桥手术 三名患者死于第二种恶性肿瘤。 1例复发患者在ABMT后死于疾病进展。 的 治疗耐受性良好，没有严重的长期 中位随访时间为7年。 很难 以改善这些结果或降低毒性。

Radiation therapy in laparotomy-staged patients with Stage I diffuse aggressive lymphomas is moderately successful. This study was designed to improve upon the efficacy of radiation therapy and to eliminate the need for staging laparotomy. In this study, clinical Stage I and IE patients are treated with four cycles of ProMACE-MOPP chemotherapy (at approximately 75% of the dosages of myelosuppressive drugs originally used in ProMACE and MOPP) followed by involved field radiation to 40 Gy. There are 62 evaluable patients entered on study of whom 60 (97%) achieved a complete remission. There have been three relapses. Seven patients died: the two who never achieved a complete response, and one woman who had been in complete response for over four years died during her second coronary artery bypass surgery. Three patients have died of a second malignancy. One relapsed patient died of progressive disease following ABMT. The treatment is well tolerated and there have been no serious long-term toxicities with a median follow-up of seven years. It would be difficult to improve upon these results or to decrease the toxicities.